Ignacio Melero Bermejo

86PUBLICATIONS

436CO-AUTHORS

Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyTumour immunology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (86)

Sort by Publication Date:

|Jul 10, 2026

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

|Jun 19, 2026

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|Jun 08, 2026

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

|May 01, 2026

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

|Apr 20, 2026

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

|Apr 07, 2026

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

Pageof 15

Frequent Collaborators

25 joint publications

Pedro Berraondo

13 joint publications

Álvaro Teijeira

13 joint publications

Maite Alvarez

12 joint publications

Iñaki Eguren-Santamaria

Miguel F Sanmamed

Emiliano Calvo Aller

Javier Glez-Vaz

Carlos Luri-Rey

Jose-Luis Perez-Gracia

8 joint publications

Carlos E de Andrea

Frequent Collaborators

25 joint publications

Pedro Berraondo

13 joint publications

Álvaro Teijeira

13 joint publications

Maite Alvarez

12 joint publications

Iñaki Eguren-Santamaria